Open AccessGefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H
Author(s) -
Huihui Guo,
Xilin Zhang,
Shangzhi Xie,
Tianwei Chen,
Da Xie,
Ying Cai,
Dawei Cui,
Liang Wang,
Wei Chen,
Xiang Wang
Publication year - 2022
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo.2022.5436
Subject(s) - gefitinib , epidermal growth factor receptor , cancer research , peripheral blood mononuclear cell , small interfering rna , immune system , cytotoxicity , biology , lung cancer , cell culture , transfection , cancer , in vitro , medicine , immunology , oncology , biochemistry , genetics